News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Instem proves in step with groundbreaking market needs as it posts strong 2022 performance

Instem PLC

Phil Reason, CEO of Instem PLC, joined Proactive with details of the company's 2022 financial performance. The company grew revenues by 28% and underlying earnings were up 32%. It also said it expected to benefit in 2023 from ‘industry consolidation’. Recent success include increased recurring revenue and a renewed contract with the US government's National Toxicology Program. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 17, 2023 03:00 AM Eastern Daylight Time

Video
Article thumbnail News Release

NuggMD Lowers Price of Medical Marijuana Evaluations to $99 to Celebrate Dispensary Openings in Georgia

NuggMD

NuggMD, the nation's leading medical marijuana telemedicine provider, is celebrating the opening of the first two dispensaries in Georgia by temporarily lowering the price of medical marijuana evaluations in that state from $139 to $99. "Georgia is finally providing legal cannabis access for its nearly 30,000 medical marijuana patients," said Collin Mann, CEO and co-founder of NuggMD. "We're thrilled to support this effort by making our services more affordable for patients in the state." In April, the Georgia Access to Medical Cannabis Commission announced that it had awarded licenses to Truelieve and Botanical Sciences to cultivate and manufacture medical cannabis. Each company will be allowed to open up to six dispensaries. The first two of these new dispensaries are owned by Truelieve and located in Marietta and Macon. Botanical Sciences will open its first dispensaries in Marietta and Pooler in July. True to form, Truelieve will keep the competition hot by opening a dispensary in Pooler also. "The opening of dispensaries in Georgia is a major milestone for the state's medical marijuana program," said Kamran Babazade, COO and co-founder of NuggMD. "Now we have to make sure we remove the remaining barriers to treatment in these uncertain economic times." "Our goal is to make it as easy as possible for patients to get the care they need," said Alex Milligan, CMO and co-founder of NuggMD. "We are committed to ensuring patients have access to safe, legal, and affordable medical cannabis." NuggMD's telemedicine platform allows patients to connect with licensed medical marijuana doctors online, making it easy and convenient to get a medical marijuana evaluation. Evaluations are available seven days a week. About NuggMD NuggMD is the nation's leading medical marijuana technology platform, serving patients in California, Connecticut, Georgia, Illinois, Iowa, Maine, Maryland, Massachusetts, Michigan, Missouri, Montana, Nevada, New Jersey, New York, Ohio, Oklahoma, Pennsylvania, Texas, Vermont, Virginia, and West Virginia. They've connected over 1,000,000 patients face-to-face with their new medical marijuana doctors via their state-of-the-art telemedicine platform. They believe every human being has the right to explore the benefits of medical cannabis and are fully committed to helping each patient explore every option in their journey to wellness. For further information, visit NuggMD.com/Georgia. Contact Details Andrew Graham +1 646-385-0189 andrew.g@getnugg.com Company Website http://www.nuggmd.com

May 16, 2023 01:41 PM Eastern Daylight Time

Article thumbnail News Release

Vivos Therapeutics talks clinical study success of POD migraine treatment, new timeline for cashflow

Vivos Therapeutics

Vivos Therapeutics chairman and CEO Kirk Huntsman joins Natalie Stoberman from the Proactive studio to discuss how the company's POD device performed a highly effective rate in treating migraine headaches in a clinical study. Huntsman says the study showed 92% of patients reporting complete resolution of their symptoms, which is an unprecedented result for a non-pharmaceutical application in this field. He adds that the device has potential for other applications, such as treating upper airway resistance, TMD, bruxism, and various pain conditions, but further research and FDA indications are required. Vivos Therapeutics has also reported an accelerated timeline for reaching positive cash flow. Huntsman says Vivos has implemented a broad set of initiatives aimed at improving operational efficiencies, reducing expenses, and positioning Vivos to take advantage of current growth opportunities. Now, the company projects it could hit the positive milestone at the beginning of 2024. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

May 16, 2023 01:19 PM Eastern Daylight Time

Video
Article thumbnail News Release

Radius boosts Scientific Advisory Board with the introduction of nine world-class advisors

Radius

Radius XR ®, the wearable digital healthcare technology brand, has added nine leading physicians and thought leaders to its Scientific Advisory Board to provide strategic scientific guidance and an insightful, hands-on perspective on the challenges eyecare professionals face. “The members of our Scientific Advisory Board are the industry’s brightest and most innovative researchers and practitioners,” said Radius CEO Ammad Khan, “and they share a passion for using technology to provide unsurpassed eye care. Their world-class expertise and insights fuel our continued drive to help professionals provide unsurpassed glaucoma care with innovative products that deliver the highest level of clinical accuracy.” Nine medical professionals at the leading edge of research and treatment Iqbal "Ike" K. Ahmed, MD, FRCSC, directs the Alan S. Crandall Center for Glaucoma Innovation and oversees its surgical therapeutics initiative. A glaucoma, cataract, and anterior segment surgeon, Dr. Ahmed has since been recognized as one of the world’s top surgeons for complex eye conditions, repeatedly named among the most influential ophthalmologists worldwide by The Ophthalmologist magazine. He is renowned for conducting groundbreaking research and device development that has advanced the surgical treatment of diseases, including glaucoma and surgical complications. A pioneer in innovative glaucoma therapeutics who coined the term “micro-invasive glaucoma surgery” (MIGS), Dr. Ahmed has been the principal investigator for numerous research studies and served as a medical monitor for many pivotal clinical trials, including the first long-term outcomes study of a MIGS device. He has published over 170 peer-reviewed papers and several books and made over 1,000 scientific presentations, including 40 visiting professor lectures worldwide. He sits on the editorial boards of Ophthalmology, Ophthalmology-Glaucoma, Journal of Glaucoma, Canadian Journal of Ophthalmology, EyeNet, Ocular Surgery News, Cataract and Refractive Surgery Today, and is a reviewer for numerous journals. In 2018, Glaucoma Today appointed him as Chief Medical Editor. Dr. Ahmed has received multiple awards, including the prestigious American Society of Cataract and Refractive Surgery's Binkhorst medal. Jason Bacharach, MD, a glaucoma consultant since 1993, is Director of Research at North Bay Eye Associates, a multi-subspecialty eyecare practice. He is also co-chair of the Department of Glaucoma at California Pacific Medical Center in San Francisco. Dr. Bacharach has served as Principal Investigator in more than 200 phase I through IV clinical trials in ophthalmology, including pharmacology and device studies related to glaucoma management and numerous other ocular diseases. A Fellow of the American Glaucoma Society and Past Chair of the American Academy’s Ophthalmic Knowledge-Based Panel for Glaucoma, Dr. Bacharach has twice been honored by the American Academy of Ophthalmology, receiving the Achievement Award in 2005 and the Secretariat Award in 2013. He travels the world extensively to lecture and has authored many articles in peer-reviewed literature and book chapters. Howard Barnebey, MD, founder of Specialty Eyecarè Centre, is one of only a few ophthalmologists in the northwest U.S. who is a cataract surgeon trained in the subspecialty of interventional ophthalmology. Throughout his career, he has remained committed to education, advancing medical innovation, and to expanding biomedical eye research. Dr. Barnebey served as a clinical assistant professor at the University of Washington, teaching residents for over 20 years, and has been a leading contributor to ophthalmology since the early 1980s, publishing articles in major medical journals. Mile Brujic, OD, FAAO, is a 2002 New England College of Optometry graduate. He is a partner of Premier Vision Group, a successful four-location optometric practice in Northwest Ohio. He practices full-scope optometry, emphasizing ocular disease management of the anterior segment, specialty contact lenses, and glaucoma. He is active at all levels of organized optometry. Dr. Brujic is on the editorial board for several optometric publications. He has published over 400 articles and given over 2000 lectures nationally and internationally on contemporary topics in eye care. April Jasper, OD, owns Advanced Eyecare Specialists, a group optometry practice in West Palm Beach, Florida. Dr. Jasper is the Chief Optometric Editor of Optometric Management magazine. She is the Director of Education for Optometric Management Education, where she shares her passion for practice management, customer service, ocular disease, and using new technology to enhance patient care and personal growth. She has experience in almost every mode of optometric practice from her VAMC residency, teaching ocular disease at NEWNCO and Benedict Professor of practice management at Houston College of Optometry, and as a 6-year leaseholder with Walmart. She is a fellow of the American Academy of Optometry and Past-President of the Florida Optometric Association. Stephen M. Montaquila, OD, FAAO, is the owner of West Bay Eye Associates in Warwick, RI. In addition to clinical practice, he is active in research for ocular therapeutics and medical devices and lectures nationally on topics relating to eye health, contact lenses, and practice management. Dr. Montaquila is a Fellow in the American Academy of Optometry and a Diplomate of the American Board of Optometry. He is the past president of the Rhode Island Optometric Association. He has served as a clinical examiner for the National Board of Examiners in Optometry and as adjunct faculty at the Massachusetts College of Pharmacy and Health Sciences. Additionally, he serves as Chair of Rhode Island Primary Care Physicians Corporation Eye Care Group. He is the immediate past Chair of the American Optometric Association Third Party Executive Committee and currently serves on the AOA Federal Relations Committee, where he works nationally with eye care coverage, reimbursement, and policy issues. Nathan M. Radcliffe, MD, is an Associate Clinical Professor of Ophthalmology at Mount Sinai School of Medicine. He is an educator, enthusiast, and early adopter of interventional glaucoma approaches, including laser, drug delivery, and micro-invasive glaucoma surgery (MIGS). He is the Director of the Glaucoma Clinical Committee of the American Society of Cataract and Refractive Surgery (ASCRS) and is the Glaucoma Day course co-director. He has published extensively in the peer-reviewed literature and is the Chief Medical Editor of the Glaucoma Physician publication. He has treated glaucoma patients in New York City and the Bronx for 14 years. I. Paul Singh, MD, President of The Eye Centers of Racine & Kenosha, Ltd., was named America’s Best Eye Doctor in 2021 by Newsweek. Dr. Singh is passionate about new technology and maintains a full-time research facility where he researches glaucoma, cataract, ocular surface disease, and retina. He was the first surgeon in Wisconsin to perform many MIGS, and the first to use newer in-office YAG lasers to perform YAG Vireolysis. He was instrumental in bringing laser-assisted cataract surgery to the area. He has been published in several ophthalmology journals and presented his research at national meetings and universities worldwide. Dagny Zhu, MD, is a nationally acclaimed, board-certified ophthalmologist and fellowship-trained cornea, cataract, and laser refractive surgery specialist. As a key opinion leader in laser vision correction and premium cataract surgery, Dr. Zhu serves on the editorial board of major ophthalmology publications, lectures to peers worldwide, and leads cutting-edge clinical research studies on the latest presbyopia treatments. She holds leadership positions in the American Academy of Ophthalmology and the American Society of Cataract and Refractive Surgery. She is a member of the prestigious AECOS and Cedars Aspens societies. Dr. Zhu was most recently named a “Top Doctor” by Castle Connolly, “Rising Star in Ophthalmology” by Super Doctors, “Top 50 Global KOL” by MediaMice, “Top 40 under 40” by Ophthalmology Management, and “Outstanding Female Leader” by Millennial Eye. The Radius XR diagnostics platform, which brings together medical-grade diagnostics, business management, and patient education tools in a single wearable device, was named a CES® 2023 Innovation Awards Honoree in both the Digital Health and Virtual & Augmented Reality categories. The entire Radius Scientific Advisory Board is listed on the company’s website at radiusxr.com/science. ### About Radius XR ( www.RadiusXR.com ) The Radius XR platform is a portable vision diagnostic and patient engagement system that combines medical-grade diagnostics, business management, and patient education tools in a wearable XR device. The RadiusExam® and proprietary algorithms provide diagnostic testing results equivalent to current exam gold standards, with the clinical science validated by Deming regression. As the algorithm presents stimuli to patients, it adapts to responses to maximize the algorithm's speed. The total hardware and software system helps medical professionals diagnose patients with accuracy, grow their eyecare practices, enhance patient engagement, and reduce staff workload by enabling patients to perform self-guided vision exams with minimal supervision. Radius builds on the therapeutic legacy of IrisVision, the first clinically validated wearable low-vision solution. IrisVision was backed by a research grant from the National Eye Institute and developed in collaboration with researchers from top ophthalmology centers at Johns Hopkins University, Stanford University, and UPMC Pittsburg. Contact Details Radius John Trefethen, Chief of Product and Marketing +1 800-607-6222 media@radiusxr.com Company Website https://www.radiusxr.com

May 16, 2023 08:04 AM Pacific Daylight Time

Article thumbnail News Release

Grow Group sees unique cross-border opportunity

Grow Group PLC

Ben Langley, CEO and Founder of Grow Group PLC, discussed the rapid growth of the medical cannabis market with Proactive's Chris Rhodes. A pioneer in the field for six years, they have seen the market expand from a few dozen patients to tens of thousands in the UK alone. They have also expanded internationally, reaching Ireland, the Channel Islands, Germany, and soon Australia. Whilst emphasising their patient-centric approach, Langley also detailed why their unique financing approach is attractive to investors and has the potential to significantly boost the industry's growth. The company aims to expand their program and involve more stakeholders, including trade finance funds and banks, to support the development of the medical cannabis sector on a larger scale. Overall, the company is in a strong position with a promising business model and a vision for further expansion. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 16, 2023 09:04 AM Eastern Daylight Time

Video
Article thumbnail News Release

AMERICAN DIVERSIFIED HOLDINGS CORPORATION ANNOUNCES THE APPOINTMENT OF ANDREW BIRNBAUM AS CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD, EFFECTIVE IMMEDIATELY

American Diversified Holdings Corp.

American Diversified Holdings Corporation (OTC: ADHC) announced today the appointment of Andrew Birnbaum as Chief Executive Officer and Chairman of the Board, effective immediately. Mr. Birnbaum brings decades of experience in running and operating companies; he has significant and successful both private and public company Chief Executive Officer experience. His leadership and effective implementation of growth and development plans will be of good use in the revitalization of the holding company. “I am very appreciative of the work that Ernest has done to this point, and I am happy to see him finally enjoy his retirement. I respect the shareholder base and will do my best to provide continued value and benefits to them.’ Stated Mr. Birnbaum, CEO And Chairman. Ernest Remo commented: “Based on Andrew’s well-rounded experience and integrity, I am very pleased with his appointment and am excited to see the new changes with the company and how they benefit our shareholders.” About ADHC: American Diversified Holdings Corporation, operates alliances with Green Global International Group (GGII), Hempaco (HPCO) and GGII Subsidiary Green Star Labs. In addition, two e-commerce sites focused on these emerging technologies: universalwellness.co (not.com) and RollsChoiceAdhesives.com. The business model includes selling products to consumers, driving traffic to partner sites, generating ad revenue and creating partnership opportunities for other wellness companies. www.adhcinvestor.com Contact Details: Andrew Birnbaum (714) 599-2126 Info@adhcinvestor.com www.adhcinvestor.com American Diversified Holdings Corporation TWITTER: @ADHCManagement. This Twitter page is the only official Twitter page for ADHC. SAFE HARBOR FORWARD-LOOKING STATEMENTS: This press release may contain forward-looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues related to our financial performance, expected revenue, contracts, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC) and on the OTC Disclosure & News Service (OTCDNS). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as “estimate,” “project,” “predict,” “will,” “would,” “should,” “could,” “may,” “might,” “anticipate,” “plan,” “intend,” “believe,” “expect,” “aim,” “goal,” “target,” “objective,” “likely” or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events or otherwise. Contact Details Andrew Birnbaum +1 714-599-2126 Info@adhcinvestor.com Company Website https://www.adhcinvestor.com/

May 16, 2023 06:00 AM Eastern Daylight Time

Article thumbnail News Release

SS Innovations International, Inc. (f/k/a Avra Medical Robotics, Inc.) Commences Trading under “SSII” Ticker Symbol and Provides Corporate Update

SS Innovations International Inc

SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger part of the global population, today released a corporate update. Recent Highlights Effective with the open of trading on Monday, May 15, 2023, SSII common stock, whose ticker symbol was AVMR, then AVMRD for 20 trading days following its merger on April 14, 2023, will begin trading under the ticker symbol “SSII”, as confirmed by FINRA on May 12, 2023. On April 19, 2023, the Company, then known as AVRA Medical Robotics, Inc., completed its merger, changed its corporate name to SS Innovations International, Inc. (“SSII”), and implemented a one-for-ten reverse stock split. SS Innovations is led by a topflight medical and engineering team including: Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “We are very excited to begin trading in the United States on OTC Markets under the ticker symbol “SSII”, the initials of the company that I founded over 10 years ago. SS Innovations has a vision to make the benefits of robotic surgery affordable and accessible to a larger part of the global population, and we are now in a stronger position to make that happen with this foothold in the American capital markets. With our flagship “SSI Mantra” Surgical Robotic System, we have now trained over 50 robotic surgeons, completed over 180 surgeries across multiple specialties on six system installations, and have a rapidly growing pipeline of system orders, initially in India. Other milestones we expect to reach this year include, the development of Mixed Reality based Robotic Surgery Applications for teaching, training, patient education and portable telesurgery. We are also developing a comprehensive robotic surgery ecosystem to centralize patients, surgeons, proctors, clinical engineers, field service technicians, radiology centers, and other key beneficiaries to provide a seamless adoption of robotic surgery around the world for basic surgical healthcare. The systems have obtained all necessary medical device regulatory and commercialization approvals in India, which are also acceptable in many other countries with certain registration processes, and will plan on commencing the FDA and CE approval processes this year. With a strong foundation in place, we look forward to meeting the growing need around the world for our cutting edge and cost effective robotic surgical systems.” About SS Innovations International, Inc. SS Innovations International, Inc. (OTC: SSII) is a developer of innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger part of the global population. SSII’s product range includes its proprietary “SSI Mantra” surgical robotic system, and “SSI Mudra” is its wide range of surgical instruments capable of supporting a variety of surgical procedures including robotic cardiac surgery. SSII’s business operations are headquartered in India and SSII has plans to expand the presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions, globally. For more information, visit SSII’s website at www.ssinnovations.com Forward-Looking Statements This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or AVRA’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. For Further Information Contact: PCG Advisory Stephanie Prince sprince@pcgadvisory.com (646) 863-6341 Contact Details Stephanie Prince sprince@pcgadvisory.com Company Website http://www.ssinnovations.com/

May 15, 2023 10:05 AM Eastern Daylight Time

Article thumbnail News Release

Kadimastem Granted European Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes

Kadimastem Ltd.

Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company, developing and manufacturing "off-the-shelf" allogeneic cell products using its platform technology to develop treatments for different neurodegenerative diseases and a potential cure for diabetes, has been granted a patent from the European Patent Office for its cell therapy technology IsletRx. IsletRx has been granted its fourth global patent approval for the company's innovative cell selection and enrichment technology, the company's treatment and potential cure for diabetes. The ability to select and enrich only the highest functioning and purest islet cells from the expanded and differentiated population of pluripotent stem cells enables the maximum therapeutic effect. Asaf Shiloni the CEO of Kadimastem stated: “The grant of this patent provides the crucial protection to our core Islet cells sorting technology, that is critical to achieve an effective cell therapy product for the treatment of diabetes. The European market holds great potential for our technology.” According to the International Diabetes Federation in 2021 “the Europe Region has the highest number of children and adolescents with type 1 diabetes – 295,000. Diabetes-related expenditure in the Europe Region totals USD 189 billion – 19.6% of its global expenditure. The Europe Region has the second highest average cost per person with diabetes (20-79y) – USD 3,086”[1]. In May 2021, the selection technology covered by this patent was described in a peer-reviewed journal article [2] in Frontiers in Endocrinology. About Kadimastem Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the company's lead product, is an astrocyte cell therapy in clinical development for the treatment for ALS and in pre-clinical studies for other neurodegenerative indications. IsletRx is the company's treatment for diabetes. IsletRx is comprised of functional, insulin and glucagon producing and releasing pancreatic islet cells, intended to treat and potentially cure patients with insulin-dependent diabetes. Kadimastem was founded by Professor Michel Revel, CSO of the company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). About IsletRx The IsletRx product is a clinical-grade collection of pancreatic islet cells. Preclinical studies have shown that the cells are able to detect the sugar levels in the body and to produce, and secrete, on demand, the required amounts of insulin and glucagon, just like a healthy pancreas and enables the insulin dependent patient to avoid an abnormal drop in sugar level (hypoglycemia). In addition, the method of production and selection of the cells enables their implantation in various types of smaller size devices, suitable for maximum comfort for people living with diabetes. [1] chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.mepinterestgroupdiabetes.eu/wp-content/uploads/2021/11/IDF-Atlas-Factsheet-2021_EUR.pdf [2] https://www.frontiersin.org/articles/10.3389/fendo.2021.635405/full At Kadimastem we envision being a global leader in cell therapy.Our passion and commitment keep us moving forward, to develop innovative regenerative therapies for incurable diseases. Our goal is to treat millions of patients around the world with that technology. This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Kadimastem Sarah Bazak +972 73-797-1601 s.bazak@kadimastem.com Company Website https://www.kadimastem.com/

May 15, 2023 07:00 AM Eastern Daylight Time

Article thumbnail News Release

Aclarion providing less invasive solution to treat lo back pain through augmented intelligence

Aclarion

Aclarion CEO Brent Ness joins Natalie Stoberman from the Proactive studio to share how the company utilizes augmented intelligence to treat chronic low back pain. Aclarion's innovative approach provides a less invasive way to pinpoint pain and offers promising results. The company's growth includes developing strong foundational technology, collaborating with key opinion leaders, and building compelling evidence through clinical trials and economic value analyses. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

May 11, 2023 12:41 PM Eastern Daylight Time

Video
1 ... 5253545556 ... 167